RAD50

DNA repair protein RAD50 · Q92878 · RAD50 on Sugi Atlas →

0 patent compounds predicted against RAD50, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to RAD50 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency PHASE2/PHASE3RECRUITING
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI PHASE1/PHASE2RECRUITING
Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer PHASE2ACTIVE_NOT_RECRUITING
A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects PHASE1/PHASE2COMPLETED
A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer PHASE1/PHASE2COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors PHASE1/PHASE2RECRUITING
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation PHASE2UNKNOWN
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors PHASE1/PHASE2RECRUITING
Olaparib In Metastatic Breast Cancer PHASE2ACTIVE_NOT_RECRUITING
Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors PHASE2COMPLETED
Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET) PHASE2RECRUITING
Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy PHASE2RECRUITING
Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation PHASE2UNKNOWN
Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd PHASE2COMPLETED
Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis PHASE2ACTIVE_NOT_RECRUITING
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies PHASE1/PHASE2RECRUITING
Chlorambucil in Metastatic PDAC Patients Bearing a Germ Line DNA Defects Repair Mutations (SALE Trial) PHASE2UNKNOWN
A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA PHASE2ACTIVE_NOT_RECRUITING
A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical Cancer PHASE2ACTIVE_NOT_RECRUITING
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer PHASE2ACTIVE_NOT_RECRUITING
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors PHASE1COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas PHASE1COMPLETED
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors PHASE1COMPLETED
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients nanCOMPLETED
Study of the Effect of Innate on the Inflammatory Response to Endotoxin nanRECRUITING
Chromosomal Translocations in Chandigarh Police nanCOMPLETED
Precision-Based Genomics in Prostate Cancer nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a RAD50 binder may also engage these)

ProteinNameSimilarity
A0A1L8GXM0 1.000 A0A1L8GXM0 →
Q9JIL8 1.000 Q9JIL8 →
P70388 1.000 P70388 →
Q9SL02 1.000 Q9SL02 →
A0A1L8GVF0 0.999 A0A1L8GVF0 →
Q54PK4 0.997 Q54PK4 →
G0SHW7 0.996 G0SHW7 →
O44199 0.996 O44199 →
Q8CG48 0.992 Q8CG48 →
Q9W252 0.992 Q9W252 →
P41003 0.991 P41003 →
Q9UTJ8 0.991 Q9UTJ8 →
P38989 0.990 P38989 →
Q9C5Y4 0.990 Q9C5Y4 →
P12753 0.990 P12753 →
Q6Q1P4 0.990 Q6Q1P4 →
Q9FLR5 0.989 Q9FLR5 →
Q9SN90 0.989 Q9SN90 →
SMC2 Structural maintenance of chromosomes protein 2 0.989 landscape →
O14777 0.988 O14777 →
Q6P9I7 0.988 Q6P9I7 →
Q90988 0.988 Q90988 →
Q802R8 0.988 Q802R8 →
Q924W5 0.987 Q924W5 →
Q4R630 0.987 Q4R630 →
O94383 0.987 O94383 →
P48996 0.987 P48996 →
A0A8M9PQ61 0.986 A0A8M9PQ61 →
G5EG17 0.986 G5EG17 →
Q9FII7 0.986 Q9FII7 →